— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit ("ELOC") and At-the-Market ("ATM") facility, as well as its outstanding number of shares. Equity Issuance Update as of End of Day November 7, 2024: Total number of shares traded since ELOC and ATM Activation: 153,085,471 Total number of shares sold via ELOC and ATM: 11,920,744, representing approximately 8% of total traded shares

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem's upcoming Special Meeting of Stockholders (the "Special Meeting"). "We believe that the proposed merger represents a compelling opportunity to accelerate Evofem's growth trajectory in women's sexual and reproductive health as a subsidiary of Aditxt," said Saundra Pelletier, CEO of Evofem. "We are making steady progress towards comp

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili"), announcing that the U.S. Food and Drug Administration ("FDA") has provided positive feedback regarding the development strategy for ATI-1801. For additional information, please visit https://finance.yahoo.com/quote/APLIF/news/. About Appili Therapeutics, Inc. Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfil its mission of solving life

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, November 1, 2024, at 11:30 AM ET. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company's latest developments and will address pre-submitted questions. This week's session will cover: Aditxt Overview and Transaction Updates Nasdaq Compliance Update Q&A Segment Participants are encouraged to engage directly by submitting questions via email or video by October 31st, 2024, at 5:00 PM ET t

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the "A&R Merger Agreement") toward completion of its intended acquisition of women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM). Today, Aditxt purchased $2.28 million of Evofem Series F-1 convertible preferred stock. This is the final investment in Evofem stipulated under the A&R Merger Agreement. Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, said, "We believe that this is a critical milestone towards the com

Event to Focus on the Status of the Acquisition, Plans Post-Acquisition for Evofem, and Q&A Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28, 2024, at 11:30 AM Eastern Time. The event will be hosted by Amro Albanna, Co-Founder and CEO of Aditxt, featuring Saundra Pelletier, CEO of Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM), and will be moderated by renowned physician and television personality Dr. Drew Pinsky. This virtual fireside chat aims to provide an update on Aditxt's acquisition of Evofem, outline post-acquisition plans, and di

Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets, and subject to the renewal of certain legislation, two programs potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili") has commenced the mailing of its management information circular in connection with the upcoming special meeting of their shareholders, which will b

Aditxt, Inc. ("Aditxt" "Company") (NASDAQ:ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM EDT. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company's latest developments and will address pre-submitted questions. This week's session will cover: Aditxt Overview and Transaction Updates: An update on the Company's current position and progress regarding the Evofem and Appili transactions. Overview of Aditxt's Current Programs: Updates on Aditxt's two ongoing progra

10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

PRE 14A - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substituting cash for Aditxt's common stock as the consideration for Evofem's common stock in the merger and additional changes relating to it. Aditxt and Evofem are diligently working to close the contemplated transaction in the second half of 2024. The closing of the transaction between Aditxt and Evofem remains subject to the successful satisfaction of a number of closing conditions, including, but not limited to, Aditxt securin

-8-K

https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/

Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.

Aditxt Inc (NASDAQ:ADTX) has agreed to acquire Evofem Biosciences Inc (OTC:EVFM) in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million. Evofem is a commercial-stage women's health company, a creator of the first and only FDA-approved hormone-free contraceptive gel, Phexxi (lactic acid, citric acid, and potassium bitartrate).  Phexxi represents a groundbreaking shift in women's healthcare, offering a non-daily, hormone-free contraceptive choice for the 23 million women who need alternatives to traditional methods in the U.S. alone.  Aditxt has assumed

Evofem posted $13.4 million in net sales of Phexxifor the first nine months of 2023;Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM), a pioneer in women's health, today announced the signing of a definitive agreement (the "Agreement") under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of

-- Padagis Determined They Will Not Challenge the Phexxi Patents --  -- Evofem Has Phexxi Patent Protection Through 2033 -- 

On Thursday May 18, 2023, the Company's common stock will open for trading under a new CUSIP (30048L302) on the OTC Venture Market, on a split-adjusted basis, under the ticker symbol "EVFMD." After 20 business days, the ticker symbol will change back to "EVFM." The reverse split will reduce the number of shares of outstanding common stock from approximately 249,004,008 shares, the number of shares outstanding as of May 17, 2023, which was the Record Date for this transaction, to approximately 1,992,032 shares. 

-Reuters

Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program, giving millions of additional women access to this innovative hormone-free contraceptive. (EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "We are pleased to partner with Costco, the largest warehouse club and third-largest retailer in America, to expand Phexxi's footprint in the cash space," said Saundra Pelletier, Chief Executive Officer of Evofem. "This program enables Costco members with no insurance or whose plans have denied coverage to fi

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.'s ("Evofem") (OTCQB:EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substit

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe

— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 81% vs. Q3 2022 — SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> $5.1 million in net product sales of Phexxi® (la

— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 68% — — Decreased loss from operations by 70% — SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2023. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "This marks the second consecutive quarter in which our

-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to positive EBITDA -- SAN DIEGO, June 16, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA break-even by year-end 2023 -- SAN DIEGO, April 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Highlights include

-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Date: Thursday, August 11, 2022 Time: 5:00 p.m. ET (2:00 p.m. PT) Live call: (877) 445-9755 (U.S. toll-free) or (201) 493-6744 Webcast (live and archived): https://evofem.investorroom.com/Update or https://www.webcast-eqs.com/register/evofem2022811/en Please connect to the webcast at least 15 min

SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13G - Evofem Biosciences, Inc. (0001618835) (Subject)

SC 13D/A - Evofem Biosciences, Inc. (0001618835) (Subject)